Compare SEB & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEB | KNSA |
|---|---|---|
| Founded | 1918 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.9B |
| IPO Year | 1994 | 2018 |
| Metric | SEB | KNSA |
|---|---|---|
| Price | $4,279.48 | $74.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $60.86 |
| AVG Volume (30 Days) | 16.8K | ★ 421.3K |
| Earning Date | 05-12-2026 | 04-28-2026 |
| Dividend Yield | ★ 0.17% | N/A |
| EPS Growth | ★ 467.71 | 225.00 |
| EPS | ★ 283.99 | 0.27 |
| Revenue | ★ $5,809,000,000.00 | $677,564,000.00 |
| Revenue This Year | N/A | $37.48 |
| Revenue Next Year | N/A | $17.87 |
| P/E Ratio | ★ $15.13 | $282.48 |
| Revenue Growth | 7.99 | ★ 60.09 |
| 52 Week Low | $3,140.01 | $35.29 |
| 52 Week High | $5,989.37 | $82.94 |
| Indicator | SEB | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 48.70 | 49.48 |
| Support Level | $4,068.17 | $44.95 |
| Resistance Level | $4,753.51 | $81.97 |
| Average True Range (ATR) | 135.53 | 2.45 |
| MACD | 30.19 | -0.82 |
| Stochastic Oscillator | 73.69 | 24.66 |
Seaboard Corp is a diversified group of companies that operate in agricultural, energy, and ocean transport businesses. The company is engaged in hog production, biofuel production, and pork processing in the United States; commodity trading and grain processing in Africa and South America; cargo shipping services in the U.S., Caribbean and Central and South America; sugar and alcohol production in Argentina; and electric power generation in the Dominican Republic. It also has an equity method investment in Butterball, LLC, a producer and processor of turkey products. The group's operating segments are; pork, commodity trading and milling, marine, liquid fuels, power, turkey, and others. It operates in 45 countries, with a concentration in the Caribbean, Central and South American region.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.